RESOURCES FOR
YOUR PATIENTS
AND PRACTICE
The comprehensive resources you
expect from the #1 prescribed HA1

The comprehensive resources you
expect from the #1 prescribed HA1
Our denial rate is <1%‡
BIs completed in ~24 hours with
online progress tracking
More than 600,000+ completed
BIs over 10 years2
Comprehensive programs such as the
Patient Direct
*The Solution Center will respond to each fax submission within
24 hours, notifying you of a patient’s coverage
via the Benefits
Investigations Report.
†The EUFLEXXA Solution Center does not file claims or
appeal-claims, and cannot guarantee that you will be
successful
in obtaining reimbursement. Third-party payment for medical
products and services is affected by
numerous factors, none of
which can be anticipated or resolved by the Solution Center.
‡The percentage of cases where the insurance company has
not made payment after benefits are verified and
claims have
been submitted.
HA=hyaluronic acid.
Preferred formulary status by many of the
largest
commercial plans, with fewer
access restrictions*
EUFLEXXA is covered under the pharmacy benefit
by many insurers such as United
Healthcare,
OptumRx, Express Scripts, and the Veterans
Administration.
*Subject to change based on individual plan coverage. Check the
member’s benefits for more details.
†Preferred access refers to favorable formulatry status, medical
policy, or fewer restrictions for EUFLEXXA.
‡Allowed for buy and bill.
§BCBS IL, BCBS MT, BCBS NM, BCBS OK, and BCBS TX.
HA=hyaluronic acid.
Patients who may participate include those with
high deductibles, patients with insurance plans
with limited coverage, and the uninsured*
Enroll your patients via fax or online through the
Solution Center. Your patients will receive a text
or email
to authorize their participation
CareMed Specialty Pharmacy will contact the
patient by
phone to confirm the prescription and
collect payment.
EUFLEXXA is shipped to your
office in 3 to 5 business days
*See eligibility criteria.
HA=hyauronic acid.
US residents who have no insurance coverage
and whose household income falls at or below 300%
of the US Federal Poverty Level are
eligible. Patients are
required to provide
income verification.
See application for additional terms and conditions
Just complete and submit the
downloadable forms
Upon determination of patient eligibility,
EUFLEXXA will be shipped to your office
Patient Assistance
Program Application
HA=hyauronic acid.
Deliver the full benefit of EUFLEXXA
with 3 injections over 3 weeks3
Injection Instructions
DownloadHA=hyaluronic acid.
If your patient is not satisfied with
their OA knee pain relief 10 weeks
after their last EUFLEXXA injection,
we offer up to a $100 refund for
copay costs. The patient must
have received 1 EUFLEXXA injection
a week x 3 weeks between
12/31/2022-12/31/2023.
Offer Terms and Conditions apply
To receive a refund, we need to receive the following from
your patient no later than 14 weeks after the last injection:
Refund form
DownloadHA=hyaluronic acid; OA=osteoarthritis.
1. Rolling 12 month average of IQVIA claims data based on unique patients (November 2021). 2. Data on file. Ferring Pharmaceuticals Inc. 3. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.
EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].
EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
Do not inject intravascularly due to potential for systemic adverse events.
The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.
Please see FULL PRESCRIBING INFORMATION.